Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $2.3 million.

  • Enanta Pharmaceuticals' Cash from Investing Activities fell 8796.2% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.3 million, marking a year-over-year decrease of 3071.69%. This contributed to the annual value of $40.3 million for FY2025, which is 3071.69% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash from Investing Activities stood at $2.3 million for Q3 2025, which was down 8796.2% from -$26.5 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $72.7 million during Q3 2021, with a 5-year trough of -$145.7 million in Q2 2023.
  • Its 5-year average for Cash from Investing Activities is $8.1 million, with a median of $16.2 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 280267.57% in 2021, then crashed by 99856.97% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $45.5 million in 2021, then fell by 26.22% to $33.6 million in 2022, then tumbled by 139.07% to -$13.1 million in 2023, then soared by 625.3% to $68.9 million in 2024, then plummeted by 96.67% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, -$26.5 million for Q2 2025, and -$4.4 million during Q1 2025.